Filing Flows › Fennec Pharmaceuticals (FENC) › Q2 2025
Fennec Pharmaceuticals (FENC) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Fennec Pharmaceuticals (FENC) reported revenue of $9.7M for the second quarter 2025 (Q2 2025), +33% from a year earlier and +10% from the quarter before. Operating margin was -28.3%, net loss $3.2M (32.7% of revenue).
Fennec Pharmaceuticals, Q2 2025: revenue $9.7M (+33% year over year), operating margin -28.3%, net loss $3.2M, operating cash flow −$3.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.7M | +10% | +33% |
| Operating profit | −$2.7M | — | — |
| Net earnings | −$3.2M | — | — |
| Operating cash flow | −$3.7M | — | — |
What changed
Revenue was $9.7M in Q2 2025, up 33% year over year and up 10% from the previous quarter.
Operating costs exceeded revenue by $2.7M, an operating margin of -28.3%. Total costs grew 1% against revenue growth of 33%. The fastest-growing cost line was Other operating costs (+59%). The quarter ended with a net loss of $3.2M, wider than the previous quarter's $1.2M loss.
Operating cash flow was −$3.7M. Non-cash charges added back $1.5M of share-based compensation. Working capital and other items used $2.0M.
Questions
What was Fennec Pharmaceuticals' revenue in the second quarter 2025?
Fennec Pharmaceuticals (FENC) reported revenue of $9.7M for the second quarter 2025 (Q2 2025), +33% from a year earlier and +10% from the quarter before.
Was Fennec Pharmaceuticals profitable in the second quarter 2025?
Operating loss was $2.7M (-28.3% of revenue) and net loss $3.2M.